What To Know About This IBD 50 Stock's 'Blowout' Quarter

Natera (NTRA) stock surged Friday after the company reported what an analyst called "blowout volume" for its cancer-detecting blood test, Signatera, in the second quarter. Signatera is a personalized blood test that looks for microscopic pieces of tumor DNA in the blood. Doctors can use it to screen for whether cancer has returned following treatment. During the second quarter, 34,000…

8/06/2026 Cancer test provider Natera is in a buy zone above a cup base ahead of second-quarter results due Thursday.

8/06/2026 Cancer test provider Natera is in a buy zone above...

Artificial intelligence can help identify and manage cyber threats, but in the hands of bad actors AI also creates new risks. (© Gary Neill)